Trial Profile
AN OPEN-LABEL, SINGLE-ARM PHASE IIIb STUDY IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION OR MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TO EVALUATE THE USABILITY OF LUCENTIS PREFILLED SYRINGE 0.5 mg
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Genentech
- 20 Jun 2016 Status changed from recruiting to completed.
- 10 Mar 2016 New trial record